Cholesterol, stroke, heart attack: a new pill could save your life

Joseph · June 28, 2025, 9:07pm

amuser · June 29, 2025, 1:19am

Already extensively discussed -

Obicetrapib (CETP inhibitor for dyslipidemia)

Continuing here a discussion that started there: Rapamycin and risk of cardiovascular disease - #3067 by AnUser (topic now closed) Obicetrapib seems extremely promising to reduce cardiovascular events and maybe also prevent diabetes and dementia (see previous discussion). Yesterday, the company behind it, NewAmsterdam Pharma, released its 2023 financial results: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update | BioSpace On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 If succesful, could it mean approval in early 2025? I’m not the only one to be excited: [Screen Shot 2024-02-29 at 11.26.48 PM] https://twitter.com/Drlipid/status/1762840999427018954 In the phase 2 trial, after 8 weeks, obicetrapib 10 mg reduced ApoB by 29.8%, non-HDL by 44.4% and Lp(a) by 56.5% and increased HDL by 165% and apolipoprotein A-I by 47.8% (P for all < .0001). (source)

Joseph · June 29, 2025, 1:29am

That was in February 2024